This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Mar 16;152(6):JC3-4.

doi: 10.7326/0003-4819-152-6-201003160-02004.

ACP Journal Club. Review: Tamoxifen, raloxifene, and tibolone prevent primary invasive breast cancer but increase risk for adverse outcomes

Affiliations

PMID: 20231558
DOI: 10.7326/0003-4819-152-6-201003160-02004

Comment

ACP Journal Club. Review: Tamoxifen, raloxifene, and tibolone prevent primary invasive breast cancer but increase risk for adverse outcomes

Joy Melnikow. Ann Intern Med. 2010.

. 2010 Mar 16;152(6):JC3-4.

doi: 10.7326/0003-4819-152-6-201003160-02004.

Author

Affiliation

¹ University of California, Davis, Sacramento, California, USA.

PMID: 20231558
DOI: 10.7326/0003-4819-152-6-201003160-02004

No abstract available

PubMed Disclaimer

Comment on

Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer.
Nelson HD, Fu R, Griffin JC, Nygren P, Smith ME, Humphrey L. Nelson HD, et al. Ann Intern Med. 2009 Nov 17;151(10):703-15, W-226-35. doi: 10.7326/0003-4819-151-10-200911170-00147. Ann Intern Med. 2009. PMID: 19920271

Similar articles

Tamoxifen, raloxifene and tibolone decrease risk of invasive breast cancer in healthy women but increase risk of thromboembolism (tamoxifen, raloxifene), endometrial cancer (tamoxifen) or stroke (tibolone).
Vogel VG. Vogel VG. Evid Based Med. 2010 Aug;15(4):122. doi: 10.1136/ebm1044. Evid Based Med. 2010. PMID: 20682726 No abstract available.
The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Wolmark N. Vogel VG, et al. Clin Breast Cancer. 2002 Jun;3(2):153-9. doi: 10.3816/CBC.2002.n.020. Clin Breast Cancer. 2002. PMID: 12123540 Clinical Trial.
Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
Ganz PA, Land SR. Ganz PA, et al. Menopause. 2008 Jul-Aug;15(4 Suppl):797-803. doi: 10.1097/gme.0b013e31817be9af. Menopause. 2008. PMID: 18596601 Review.
Breast cancer risk management.
Reeder JG, Vogel VG. Reeder JG, et al. Clin Breast Cancer. 2007 Dec;7(11):833-40. doi: 10.3816/CBC.2007.n.047. Clin Breast Cancer. 2007. PMID: 18269772 Review.
The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.
Lee WL, Cheng MH, Chao HT, Wang PH. Lee WL, et al. Taiwan J Obstet Gynecol. 2008 Mar;47(1):24-31. doi: 10.1016/S1028-4559(08)60051-0. Taiwan J Obstet Gynecol. 2008. PMID: 18400579 Review.

See all similar articles

Cited by

Combined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trial.
Yang H, Zong X, Yu Y, Shao G, Zhang L, Qian C, Bian Y, Xu X, Sun W, Meng X, Ding X, Chen D, Zou D, Xie S, Zheng Y, Zhang J, He X, Sun C, Yu X, Ni J. Yang H, et al. Br J Cancer. 2013 Aug 6;109(3):582-8. doi: 10.1038/bjc.2013.324. Epub 2013 Jul 16. Br J Cancer. 2013. PMID: 23860520 Free PMC article. Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Atypon